Brodalumab治疗银屑病关节炎:III期AMVISION-1和AMVISION-2试验结果
两项随机III期试验比较了Brodalumab(白介素-17受体A亚单位抑制剂)与安慰剂在活动性银屑病关节炎患者中的疗效与安全性。研究因申办方决定提前终止,共随机962例患者。第16周时Brodalumab 140mg和210mg组ACR20应答率分别为45.8%和47.9%,显著高于安慰剂组的20.9%(p<0.0001)。Brodalumab耐受性良好,安全性与其他白介素-17抑制剂一致。
要点
- Brodalumab显著提高第16周ACR20应答率(45.8%和47.9% vs 20.9%,p<0.0001)。
- ACR50/70、PASI75/90/100及指炎和附着点炎缓解均显著优于安慰剂(p<0.01)。
- 不良事件发生率组间相似(54.4%、51.6%和54.5%),未发现新安全性信号。
核心结论
- Brodalumab相比安慰剂能快速且显著改善银屑病关节炎的体征和症状。
- Brodalumab耐受性良好,安全性特征与其他白介素-17抑制剂一致。
研究设计与样本
- 两项III期随机双盲安慰剂对照试验(NCT02029495和NCT02024646)。
- 纳入对传统治疗应答不足或不耐受的活动性银屑病关节炎成年患者。
- 按1:1:1随机接受皮下Brodalumab 140mg、210mg或安慰剂,第0、1周给药后每2周一次至24周。
- 约30%患者既往使用过生物制剂。
- 共随机962例患者,研究因申办方决定提前终止。
主要发现
- 第16周ACR20应答率:Brodalumab 140mg组45.8%,210mg组47.9%,安慰剂组20.9%(p<0.0001)。
- 第24周观察到相似结果。
- Brodalumab组达到ACR50/70、PASI75/90/100及指炎和附着点炎缓解的患者比例显著高于安慰剂(p<0.01)。
- 第16周不良事件发生率:安慰剂组54.4%,Brodalumab 140mg组51.6%,210mg组54.5%。
- 未报告新的安全性信号。
关键数值与推荐
- 主要终点为第16周ACR20应答率。
- 两项研究均达到主要终点。
- 因设计可比且入选标准一致,两项研究数据被汇总分析。
临床怎么用
- Brodalumab可作为活动性银屑病关节炎患者(包括部分既往生物制剂暴露者)的一种治疗选择。
- 治疗第16周即可评估ACR20应答,第24周应答持续。
局限性
- 两项研究因申办方决定提前终止。
- 约30%患者有既往生物制剂使用史,其余患者数据未详细报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacy and safety of brodalumab, an interleukin-17 receptor subunit A inhibitor, with placebo, in patients with psoriatic arthritis (PsA). METHODS: Adult patients with active PsA and inadequate response to, or intolerance to, conventional treatment were enrolled into two phase III studies (NCT02029495 and NCT02024646) and randomised 1:1:1 to receive subcutaneous brodalumab 140 mg or 210 mg or placebo at weeks 0, 1 and every 2 weeks up to 24 weeks. About 30% of patients had prior use of biologics. The primary endpoint for both studies was the American College of Rheumatology 20 (ACR20) response at week 16. RESULTS: 962 patients were randomised across the studies prior to early termination due to sponsor decision. The primary endpoint was met in both studies. Based on comparable design and eligibility criteria, data from both studies were pooled. Significantly more patients achieved ACR20 at week 16 in both brodalumab treatment groups (45.8% and 47.9% for 140 mg and 210 mg, respectively) versus placebo (20.9%) (p<0.0001). Similar results were observed at week 24. Significantly higher proportions of patients receiving brodalumab achieved ACR50/70, Psoriasis Area and Severity Index 75/90/100 and resolution of dactylitis and enthesitis versus placebo (p<0.01). Adverse event rates were similar across treatments at week 16 (54.4%, 51.6% and 54.5% for placebo, brodalumab 140 mg and 210 mg, respectively). No new safety signals were reported. CONCLUSION: Brodalumab was associated with rapid and significant improvements in signs and symptoms of PsA versus placebo. Brodalumab was well tolerated, with a safety profile consistent with other interleukin-17 inhibitors.
引用
- Mease PJ, Helliwell PS, Hjuler KF, et al. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Ann Rheum Dis. 2020. PMID: 33106286. doi:10.1136/annrheumdis-2019-216835
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。